Tag: Cellestial
-
#Killer50: Celebrating Cambridge Cluster
It is our great pleasure at Cellestial Health to be recognised alongside our outstanding peers in the Cambridge ecosystem at the annual #Killer50 2026 event by Business Weekly.We will strive to continue delivering advancements in the treatment of brain disorders for the benefit of patients and the scientific community. With gratitude, always 🙏 About #Killer50:Organised…
-
Insights from the BMCS Spring Symposium on Medicinal Chemistry
On Thursday 23rd April 2026, Medicinal Chemistry adviser of Cellestial Health, Lewis Pennicott, attended and contributed to the discussion at the 37th BMCS Spring Symposium on Medicinal Chemistry, the heart of the med chem community. He reports: Fantastic day at the Fielder Centre for the #HatfieldMedChem symposium. Staying at the forefront of these technical advancements…
-
Cellestial Health Joins ET Capital Portfolio and Secures Strategic Support
27th of April 2026; Cambridge, UK Cellestial Health, a biopharmaceutical company developing a new class of drugs for Parkinson’s which affects over 10 million people in the world, is pleased to have recently joined the portfolio of the Cambridge Venture Index Fund (CVIF) of ET Capital – a fund supporting diversified deep science companies spinning out…
-
One Nucleus Awards Gala
Last Thursday 19th of March brought the UK-wide life sciences ecosystem leaders together for a very special occasion of the #ONAwards26 celebration at No.11 Cavendish Square in London. It was a great honour to have the project between Cellestial and The University of Manchester, supported by a Parkinson’s UK grant, recognised as one of the finalist entries in the “Best Industry and…
-
Best Industry and Not for Profit Collaboration: Finalists
The annual One Nucleus Awards dinner celebrates the excellence of the diverse Life Sciences sector, recognising all parts of the community. One Nucleus believe that it is the interactions and dynamics of the entire ecosystem that lead to successful value and impact creation, the vision that resonates with our team’s. This year, the collaboration between…
-
Back at it again in Boston
This week, Dr Nat Hastings represented innovative research into astrocyte pathology in Parkinson’s at the 14th Alzheimer’s & Parkinson’s Drug Development Summit on behalf of Cellestial Health at Hyatt Regency Boston Harbor. Astrocytic lineage is one of the most populous cell types in the brain, yet the damage Parkinson’s pathology does to it remains underappreciated.…
-
BioSeed 2026: What Matters
On Monday 19th of January, the Cellestial Team attended BioSeed by OBN to re-connect with the London life sciences community and share why our approach to astrocytic network restoration matters in Parkinson’s. ✦ For brain cells, we are looking to reduce the burden of abnormal protein aggregates and inflammation via a novel mechanism✦ For people…
-
Cellestial Health officially opens Seed funding round
On Monday 17th of November, at the LSX Investival 2025 and at the start of the Jeffries week in London, Dr Nat Hastings (CEO) and Dr Peter Bach (Head of Drug Development) of Cellestial Health have officially opened the Seed fundraise. This follows on from a strong year post-Pre-Seed funding, featuring:✦ Proof-of-concept studies in disease-relevant…
-
BMCS and Parkinson’s UK: New Approaches to the Treatment of Parkinson’s
Dr Nat Hastings represented Cellestial Health at the RSC BMCS and Parkinson’s UK “New Approaches to the Treatment of Parkinson’s” conference on Wednesday 12th, alternating between the corporate exhibitor stand, academic poster presenter, and an audience member of the many insightful talks at the majestic Royal Society of Chemistry halls. Here are the highlights of…
-
One Nucleus #BioWednesday: Ones to Watch in Neuroscience
On Wednesday 22nd of October, a number of select innovative companies presented 5-minute pitches at the One Nucleus BioWednesday evening dedicated to Neuroscience. The opening pitch was delivered by Dr Nat Hastings on behalf of Cellestial Health, discussing our pipeline of small molecule therapeutics designed to protect astrocytic networks and slow down Parkinson’s. A mix…